Thursday, October 16, 2014

Medicare release of 2012 Part B data

Recently the Centers for Medicare and Medicaid Services (CMS) released Medicare provider utilization and payment data to the public. The data released accounts for a relatively small and biased view of total Medicare spending (Table 1). Nonetheless, it does make public the cost, to both Medicare and to patients, of most of the procedures performed for seniors in the United States.

Table 1 - Understanding the data. The Medicare data release contains a subset of Medicare Part B.  Spending for the “Part B data release” row was computed directly from the data. Otherwise, spending reported here was derived from this article.
Medicare
Spending (billions of dollars)
Description
Part A
$214
Hospital fees, home health, skilled nursing
Part B
$145
"Medically necessary" services and supplies
Advantage Plans
$123
Accountable care and other risk sharing arrangements
Part D
$54
Drugs
Part B data release
$77
Filtered to protect patient anonymity. Contains cases where physician performed procedure > 10 times.

We have seen a number of articles recently utilizing the data (1,2) to focus on the large sums of money being collected from Medicare by relatively few physicians.  This should not, however, be particularly surprising, as the 80/20 principle is a relatively ubiquitous phenomenon in many industries.  On the other side of the healthcare coin, similar observations (1,2) have been made regarding a relatively small percentage of patients who account for a large percentage of overall healthcare spending.

Before digging into this data it is worth understanding some of its weaknesses. First, the data has been filtered in order to protect the anonymity of patients.  Specifically, if a physician has performed a particular procedure less than 10 times, then data on that procedure from that physician isn’t available. Second, the data covers only Medicare Part B “fee-for-service” claims from 2012.

Because of the type of data filtering being used, non-specialists – who may not meet the 10-time threshold on any particular procedure – appear to collect a lower percentage of the Medicare dollars than they actually do. This filtering plus unavailable data from Parts A, C and D make articles claiming that particular portions of the pie go to particular individuals somewhat suspect.

While in the process of analyzing the CMS physician payment data it is tempting to focus on the practices of individual physicians – the data lists the names and work addresses of over 880,000 different healthcare providers – that should not be the main purpose of this data.  In addition to that, because of the biased filtering and missing data from Medicare Parts A, C and D, it isn’t even what the data is best suited for. 

In a companion article to this one, we look at the prices of various treatments that are approved by the FDA and paid for by Medicare.  This data release offers the opportunity to examine the way that Medicare pricing combined with healthcare market forces lead to decisions about the value of human life. If by releasing it CMS makes it possible to move our healthcare system closer to a free market – in which providers compete on prices and quality metrics that are transparent – then we are closer to addressing the inefficiencies and huge costs of our healthcare system.

List of procedures that cost Medicare (and patients) the most money

Data from the recently released Medicare provider utilization and payment data contain cost information for over 5000 procedures performed for seniors in the United States in 2012. The data is a little complicated and contains some biases.  However, with a little care it is possible to identify the most expensive procedures and get an understanding of the monetary value our healthcare system has assigned to human life.

The costs that are reported in the data set are for a single procedure. However, if a course of therapy requires that a procedure be repeated multiple times, then the real cost is higher. In order to get an understanding of annual cost, we need the number of procedures in a course of therapy. To get this we divide the number of times a procedure was completed by the number of unique patients receiving that procedure (both available in the data). This is still an underestimate because we only have data on procedures performed in 2012 while the course of therapy may have extended into either 2011 or 2013.

 The table lists 37 therapeutic options that cost more that $10,000 for a course of therapy in 2012. Focusing just on treatments for cancer that are listed in the table (in orange) we see that the value of a month of life varies from $2,333 for Oxaliplatin to treat colorectal cancer to $29,709 for Ipilimumab to treat melanoma.

By not specifically setting a price on human life, we are allowing the free(ish) market to make those decisions. That isn't inherently good or bad, but free market in the American healthcare system is distorted by perverse incentives and high levels of information asymmetry. The patients, physicians, payers and makers of therapeutics all have vastly different levels of understanding of the value and cost of therapies. In a later article, we will look at some specific examples of how this leads to therapeutic decisions that aren't necessarily optimal for patients.


Code
Procedure
Therapeutic Indication
Average Allowed Payment
patients in dataset
Bosted overall survival (months)
Cost per month of life ($)
J7192
Factor viii recombinant NOS
Hemophelia
249877.5
357
continuous
20,823
J7187
Humate-P, inj              
Hemophelia
211461.2
12
continuous
17,622
J7193
Factor IX non-recombinant  
Hemophelia
186561.1
13
continuous
15,547
J7195
Factor IX recombinant      
Hemophelia
185380.8
43
continuous
15,448
J1786
Imuglucerase injection     
Hemophelia
133782.8
35
continuous
11,149
J7190
Factor viii                
Hemophelia
132205.5
55
continuous
11,017
J9228
Ipilimumab injection       
Melanoma
118836.5
71
4
29,709
Q2043
Sipuleucel-T auto CD54+    
Prostate cancer
63459.8
274
4.1
15,478
Q3025
IM inj interferon beta 1-a 
Multiple sclerosis
28033.83
17
J1561
Gamunex/gamunex c          
Primary Immuno- deficiency
26335.92
1393
Continuous
2,195
J9043
Cabazitaxel injection      
Prostate Cancer
25994.92
29
2.4
10,831
J2353
Octreotide injection, depot
Cancer supportive care
20100.57
906
J0490
Belimumab injection        
Lupus
19702.11
122
J2796
Romiplostim injection      
Chronic ITP
18650.44
82
Continuous
1,554
J9055
Cetuximab injection        
colorectal cancer  head/neck cancer
18291.55
708
colorectal: 1.1  head/neck: .8
colorectal: 16,628 head/neck: 22,864
77523
Proton trmt intermediate   
various cancers
17700.16
887


L8687
Implt nrostm pls gen dua rec
16881.23
95
J9305
Pemetrexed injection       
lung cancer
16869.75
3048
non-squamous: 2.8  mesothelioma: 2.8
non-squamous: 6,025 mesothelioma: 6,025
0182T
Hdr elect brachytherapy    
various cancers
16852.01
540


J2323
Natalizumab injection      
Crohn's disease, multiple sclerosis
16348.39
2716
J1572
Flebogamma injection       
Primary Immuno- deficiency
15625.81
209
Continuous
1,302
J9310
Rituximab injection        
Leukemia, lymphoma
15078.95
35654
J2562
Plerixafor injection       
non-Hodgkin lymphoma, multiple myeloma
14181.41
12
J9355
Trastuzumab injection      
HER2 Gastric cancer    HER2 Breast cancer
13762.43
2773
Gastric: 2.4
5,734
37231
Tib/per revasc stent & ather
revascular- ization surgery
13452.13
441


J1745
Infliximab injection       
Crohn's, Ulcerative Colitis, Arthritis
13430.7
42645
J1568
Octagam injection          
Primary Immuno- deficiency
12171.14
1397
Continuous
1,014
77600
Hyperthermia treatment     
various cancers
12111.14
77


J1569
Gammagard liquid injection 
Primary Immuno- deficiency
11939.5
1586
Continuous
995
J1459
Inj IVIG privigen 500 mg   
Primary Immunodeficiency, Chronic ITP
11832.02
663
Continuous
986
37227
Fem/popl revasc stnt & ather
revascular- ization surgery
11535.57
4319


J9263
Oxaliplatin                
Colorectal cancer
11196.69
8164
4.8
2,333
J3262
Tocilizumab injection      
Rheumatoid arthritis
10997.55
2216
Continuous
916
36516
Apheresis selective        
Various
10901.78
42


J9264
Paclitaxel protein bound   
pancreatic cancer, lung cancer, breast cancer
10605.92
1041
pancreatic: 1.8 
pancreatic: 5,892
J0129
Abatacept injection        
Arthritis
10231.23
13916
Continuous
853
J2357
Omalizumab injection       
asthma, idiopathic urticaria
10042.75
2770
Continuous
837